Solidification or crystallization of phase change emulsion in the form of fine emulsion drops in a direct contact coolant at temperatures below their freezing point was studied. This work is mainly focused on the size...Solidification or crystallization of phase change emulsion in the form of fine emulsion drops in a direct contact coolant at temperatures below their freezing point was studied. This work is mainly focused on the size and shape of the generated partides from phase change emulsified fats. Size of the particles is the major or key factor being considered during their formation, however, other factors that govern the particle size and shape were also observed. The operating parameters of the process were optimized in order to obtain particles of smaller size ranges in the window of current operating conditions. The crystallization of complex emulsion maffices is very difficult to control in the bulk at desired requirement. Hence, the emulsion drop to particle formation has advan- tage in comparison with the bulk solidification or crystallization. The main objective of this work is to achieve spherical emulsion particles in a direct contact cooling system. Parameters like： stat）ility, characterization, viscos- ity, and the effect of different energy inputs were examined. Moreover, the effects of the capillary size, interracial tension, temperature of the emulsion on the particle size were also monitrored.展开更多
As crucial factors in hepatitis C virus(HCV)management,resistance-associated substitutions(RASs)are associated with the treatment outcome of some direct-acting antiviral(DAA)-based regimens.In this study,we mainly ana...As crucial factors in hepatitis C virus(HCV)management,resistance-associated substitutions(RASs)are associated with the treatment outcome of some direct-acting antiviral(DAA)-based regimens.In this study,we mainly analyzed the impact of baseline Y93 H or Y93 Y/H on the short-term efficacy after single administration of NS5 A inhibitors in three phaseⅠb clinical trials(yimitasvir phosphate,KW-136 and fopitasvir),and analyzed the prevalence of baseline RASs and treatment-emergent RASs.A total of 94 treatment-naive HCV genotype(GT)-1 b(n=63)and GT-2 a(n=31)Chinese patients were enrolled in three phase lb clinical trials.We investigated RASs in 77 patients with next generation or Sanger sequencing.In the 7-day trial of yimitasvir phosphate,the mean maximum HCV RNA decrease of patients with baseline Y93 H or Y93 Y/H was lower than that of patients without the mutation in the 30 mg and 200 mg cohorts(0.83 vs.2.45 log10 IU/mL and 1.92 vs.2.63 log10 IU/mL).In the3-day trial of KW-136,the mean maximum HCV RNA decrease in patients with baseline Y93 H or Y93 Y/H was lower than that of patients without the mutation in the 30,60 and 120 mg cohorts(1.58 vs.2.89 log10 IU/mL,3.16 vs.4.09 log10 IU/mL and3.00 vs.5.04 log10 IU/mL,respectively).In the 3-day trial of fopitasvir,only 30 mg group had baseline Y93 H or Y93 Y/H,and the average maximum HCV RNA decrease of patients with baseline Y93 H or Y93 Y/H was lower than that of patients without the mutation(1.45 vs.3.59 log10 IU/mL).In the three trials,baseline RASs were observed in 54 patients(70.1%;54/77).The most prevalent baseline RASs were Y93 H and Y93 Y/H(18.2%;14/77),followed by L3 IM(16.9%;13/77).The most common RASs after single administration of DAA were Y93 H and Y93 Y/H.Our data could provide reference for future clinical treatment and clinical trial.展开更多
基金the Department of Chemical Engineering,COMSATS Institute of Information Technology,Lahore,Pakistan,for relieving them from their duties,and Higher Education Commission,Pakistan(A/07/96851)for providing the financial assistance to carry out Ph D study in cooperation with the German Academic Exchange Service(DAAD)
文摘Solidification or crystallization of phase change emulsion in the form of fine emulsion drops in a direct contact coolant at temperatures below their freezing point was studied. This work is mainly focused on the size and shape of the generated partides from phase change emulsified fats. Size of the particles is the major or key factor being considered during their formation, however, other factors that govern the particle size and shape were also observed. The operating parameters of the process were optimized in order to obtain particles of smaller size ranges in the window of current operating conditions. The crystallization of complex emulsion maffices is very difficult to control in the bulk at desired requirement. Hence, the emulsion drop to particle formation has advan- tage in comparison with the bulk solidification or crystallization. The main objective of this work is to achieve spherical emulsion particles in a direct contact cooling system. Parameters like： stat）ility, characterization, viscos- ity, and the effect of different energy inputs were examined. Moreover, the effects of the capillary size, interracial tension, temperature of the emulsion on the particle size were also monitrored.
基金Jilin University Science and Technology Innovative Research Team(Grant No.2017TD-08)。
文摘As crucial factors in hepatitis C virus(HCV)management,resistance-associated substitutions(RASs)are associated with the treatment outcome of some direct-acting antiviral(DAA)-based regimens.In this study,we mainly analyzed the impact of baseline Y93 H or Y93 Y/H on the short-term efficacy after single administration of NS5 A inhibitors in three phaseⅠb clinical trials(yimitasvir phosphate,KW-136 and fopitasvir),and analyzed the prevalence of baseline RASs and treatment-emergent RASs.A total of 94 treatment-naive HCV genotype(GT)-1 b(n=63)and GT-2 a(n=31)Chinese patients were enrolled in three phase lb clinical trials.We investigated RASs in 77 patients with next generation or Sanger sequencing.In the 7-day trial of yimitasvir phosphate,the mean maximum HCV RNA decrease of patients with baseline Y93 H or Y93 Y/H was lower than that of patients without the mutation in the 30 mg and 200 mg cohorts(0.83 vs.2.45 log10 IU/mL and 1.92 vs.2.63 log10 IU/mL).In the3-day trial of KW-136,the mean maximum HCV RNA decrease in patients with baseline Y93 H or Y93 Y/H was lower than that of patients without the mutation in the 30,60 and 120 mg cohorts(1.58 vs.2.89 log10 IU/mL,3.16 vs.4.09 log10 IU/mL and3.00 vs.5.04 log10 IU/mL,respectively).In the 3-day trial of fopitasvir,only 30 mg group had baseline Y93 H or Y93 Y/H,and the average maximum HCV RNA decrease of patients with baseline Y93 H or Y93 Y/H was lower than that of patients without the mutation(1.45 vs.3.59 log10 IU/mL).In the three trials,baseline RASs were observed in 54 patients(70.1%;54/77).The most prevalent baseline RASs were Y93 H and Y93 Y/H(18.2%;14/77),followed by L3 IM(16.9%;13/77).The most common RASs after single administration of DAA were Y93 H and Y93 Y/H.Our data could provide reference for future clinical treatment and clinical trial.
